S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Biden signs bill extending a key US surveillance program after divisions nearly forced it to lapse
Closing prices for crude oil, gold and other commodities
MarketBeat Week in Review – 4/15 - 4/19
The drug war devastated Black and other minority communities. Is marijuana legalization helping?
Crews turn sights to removing debris from ship's deck in Baltimore bridge collapse cleanup
A man escaped Sudan's bloody civil war. His mysterious death in Missisippi has sparked suspicion
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Biden signs bill extending a key US surveillance program after divisions nearly forced it to lapse
Closing prices for crude oil, gold and other commodities
MarketBeat Week in Review – 4/15 - 4/19
The drug war devastated Black and other minority communities. Is marijuana legalization helping?
Crews turn sights to removing debris from ship's deck in Baltimore bridge collapse cleanup
A man escaped Sudan's bloody civil war. His mysterious death in Missisippi has sparked suspicion
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Biden signs bill extending a key US surveillance program after divisions nearly forced it to lapse
Closing prices for crude oil, gold and other commodities
MarketBeat Week in Review – 4/15 - 4/19
The drug war devastated Black and other minority communities. Is marijuana legalization helping?
Crews turn sights to removing debris from ship's deck in Baltimore bridge collapse cleanup
A man escaped Sudan's bloody civil war. His mysterious death in Missisippi has sparked suspicion
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Biden signs bill extending a key US surveillance program after divisions nearly forced it to lapse
Closing prices for crude oil, gold and other commodities
MarketBeat Week in Review – 4/15 - 4/19
The drug war devastated Black and other minority communities. Is marijuana legalization helping?
Crews turn sights to removing debris from ship's deck in Baltimore bridge collapse cleanup
A man escaped Sudan's bloody civil war. His mysterious death in Missisippi has sparked suspicion
NASDAQ:BTAI

BioXcel Therapeutics (BTAI) Stock Price, News & Analysis

$2.75
+0.20 (+7.84%)
(As of 04/19/2024 ET)
Today's Range
$2.52
$2.79
50-Day Range
$1.95
$3.59
52-Week Range
$1.91
$29.56
Volume
619,867 shs
Average Volume
418,583 shs
Market Capitalization
$84.10 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$16.86

BioXcel Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Hold
2.43 Rating Score
Upside/​Downside
513.0% Upside
$16.86 Price Target
Short Interest
Healthy
10.54% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.13
Upright™ Environmental Score
News Sentiment
0.76mentions of BioXcel Therapeutics in the last 14 days
Based on 15 Articles This Week
Insider Trading
Selling Shares
$17,046 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($2.46) to ($1.85) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.38 out of 5 stars

Medical Sector

110th out of 911 stocks

Pharmaceutical Preparations Industry

36th out of 418 stocks

BTAI stock logo

About BioXcel Therapeutics Stock (NASDAQ:BTAI)

BioXcel Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI, a sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The company also continues to conduct clinical trials evaluating BXCL501 for the acute treatment of agitation in Alzheimer's disease patients, and for adjunctive treatment of patients with major depressive disorder, as well as in the community for agitation associated with bipolar disorders and schizophrenia. In addition, it is developing BXCL502 as a potential therapy for chronic agitation in dementia; and BXCL701, an investigational, orally innate immunity activator for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors; BXCL503, a drug candidate to target apathy in dementia; and BXCL504, a drug candidate to target aggression in dementia. BioXcel Therapeutics, Inc. was incorporated in 2017 and is headquartered in New Haven, Connecticut.

BTAI Stock Price History

BTAI Stock News Headlines

Secret Bull Market Starts in This Unusual Sector
"We're only at the very beginning of a new wave that could deliver 500%-plus gains in the years to come." In fact, 50 small companies related to this sector have already soared 100% or more in a recent 90-day stretch.
Secret Bull Market Starts in This Unusual Sector
"We're only at the very beginning of a new wave that could deliver 500%-plus gains in the years to come." In fact, 50 small companies related to this sector have already soared 100% or more in a recent 90-day stretch.
BioXcel Therapeutics CCO sells $2.6k in stock
See More Headlines
Receive BTAI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioXcel Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/12/2024
Today
4/20/2024
Next Earnings (Estimated)
5/13/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:BTAI
Fax
N/A
Employees
74
Year Founded
2017

Price Target and Rating

Average Stock Price Target
$16.86
High Stock Price Target
$40.00
Low Stock Price Target
$4.00
Potential Upside/Downside
+513.0%
Consensus Rating
Hold
Rating Score (0-4)
2.43
Research Coverage
7 Analysts

Profitability

Net Income
$-179,050,000.00
Net Margins
-12,974.86%
Pretax Margin
-12,974.86%

Debt

Sales & Book Value

Annual Sales
$1.38 million
Book Value
($1.89) per share

Miscellaneous

Free Float
19,630,000
Market Cap
$84.10 million
Optionable
Optionable
Beta
0.40

Social Links

10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

  • Dr. Vimal D. Mehta Ph.D. (Age 62)
    Founder, CEO, President, & Director
    Comp: $1.76M
  • Mr. Javier Rodriguez (Age 51)
    Senior VP, Chief Legal Officer & Corporate Secretary
    Comp: $638.88k
  • Mr. Matthew Wiley (Age 51)
    Senior VP & Chief Commercial Officer
    Comp: $620.12k
  • Mr. Richard I. Steinhart MBA (Age 67)
    Senior VP & CFO
    Comp: $404k
  • Dr. Frank D. Yocca Ph.D. (Age 67)
    Senior VP & Chief Scientific Officer
    Comp: $452.58k
  • Dr. Vincent J. O'Neill B.Sc. (Age 55)
    M.D., M.R.C.P., Executive VP and Chief of Product Development & Medical Officer
    Comp: $510.17k
  • Dr. Chetan D. Lathia Ph.D.
    Senior VP and Head of Translational Medicine, Clinical Pharmacology & Regulatory Affairs
  • Dr. Robert Risinger M.D.
    Chief Medical Officer - Neuroscience

BTAI Stock Analysis - Frequently Asked Questions

Should I buy or sell BioXcel Therapeutics stock right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for BioXcel Therapeutics in the last year. There are currently 4 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" BTAI shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BTAI, but not buy additional shares or sell existing shares.
View BTAI analyst ratings
or view top-rated stocks.

What is BioXcel Therapeutics' stock price target for 2024?

7 analysts have issued 12 month target prices for BioXcel Therapeutics' stock. Their BTAI share price targets range from $4.00 to $40.00. On average, they expect the company's share price to reach $16.86 in the next year. This suggests a possible upside of 513.0% from the stock's current price.
View analysts price targets for BTAI
or view top-rated stocks among Wall Street analysts.

How have BTAI shares performed in 2024?

BioXcel Therapeutics' stock was trading at $2.95 at the start of the year. Since then, BTAI shares have decreased by 6.8% and is now trading at $2.75.
View the best growth stocks for 2024 here
.

Are investors shorting BioXcel Therapeutics?

BioXcel Therapeutics saw a decrease in short interest during the month of March. As of March 31st, there was short interest totaling 2,490,000 shares, a decrease of 20.7% from the March 15th total of 3,140,000 shares. Based on an average daily volume of 1,490,000 shares, the short-interest ratio is presently 1.7 days. Approximately 10.5% of the shares of the company are sold short.
View BioXcel Therapeutics' Short Interest
.

When is BioXcel Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024.
View our BTAI earnings forecast
.

How were BioXcel Therapeutics' earnings last quarter?

BioXcel Therapeutics, Inc. (NASDAQ:BTAI) announced its quarterly earnings data on Tuesday, March, 12th. The company reported ($0.76) earnings per share for the quarter, topping analysts' consensus estimates of ($0.98) by $0.22. The business earned $0.38 million during the quarter, compared to analysts' expectations of $1.17 million. BioXcel Therapeutics had a negative net margin of 12,974.86% and a negative trailing twelve-month return on equity of 890.63%.

What ETF holds BioXcel Therapeutics' stock?

iShares Neuroscience and Healthcare ETF holds 2,477 shares of BTAI stock, representing 0.39% of its portfolio.

What other stocks do shareholders of BioXcel Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BioXcel Therapeutics investors own include NVIDIA (NVDA), Alibaba Group (BABA), CRISPR Therapeutics (CRSP), JD.com (JD), Inseego (INSG), Marvell Technology (MRVL), Invitae (NVTA), Tesla (TSLA), Advanced Micro Devices (AMD) and Editas Medicine (EDIT).

When did BioXcel Therapeutics IPO?

BioXcel Therapeutics (BTAI) raised $60 million in an initial public offering on Thursday, March 8th 2018. The company issued 5,000,000 shares at a price of $11.00-$13.00 per share. Barclays, UBS Investment Bank and BMO Capital Markets acted as the underwriters for the IPO and Canaccord Genuity was co-manager.

How do I buy shares of BioXcel Therapeutics?

Shares of BTAI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:BTAI) was last updated on 4/20/2024 by MarketBeat.com Staff

From Our Partners